Recent Updates
Recently added Catalysts
TPST Positive Sentiment

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tempest has reported its financial results for Q2 2026 and announced a collaboration with Senlang Biotechnology. This partnership aims to advance the development of TPST-4003, a next-generation CAR-T therapy targeting CD7. The first patient is expected to be dosed in the fourth quarter of 2026, with initial clinical data anticipated shortly thereafter.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with Senlang Biotechnology enhances product development.
  • Anticipated first patient dosing for TPST-4003 in Q4 2026.
  • Initial clinical data expected soon after dosing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
10.6%
average across 2 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
ATR-101
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first

Frequently Asked Questions

What collaboration did Tempest announce?

Tempest announced a development collaboration with Senlang Biotechnology.

What is TPST-4003?

TPST-4003 is a CD7-targeted next-generation in vivo CAR-T product candidate.

When is the first patient dosing for TPST-4003 expected?

The first patient dosing for TPST-4003 is anticipated in the fourth quarter of 2026.

When will initial clinical data be available?

Initial clinical data for TPST-4003 is expected after the first patient dosing.

ShareAdd on Google
Tags: TPST Viatris Investor Conferences Healthcare CAR-T Senlang Biotechnology TPST-4003 clinical data
Last updated: Aug 13, 2026

Biotech snapshot

Cash runway
$2M liquidity · $3M/mo burn
~0 mo
High dilution risk
Lead asset
ATR-101Phase 2
Congenital Adrenal Hyperplasia →

Catalyst track record

+41%
best trade around TPST's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TPST.

See every catalyst's timing & PoA →